Employment, work disability, and work days lost in patients with ankylosing spondylitis: a cross sectional study of Dutch patients - Wikidata - wikimedia - TriplyDB

Employment, work disability, and work days lost in patients with ankylosing spondylitis: a cross sectional study of Dutch patients

Employment, work disability, and work days lost in patients with ankylosing spondylitis: a cross sectional study of Dutch patients

http://www.wikidata.org/entity/Q35550292

about

TNF-alpha inhibitors for ankylosing spondylitis TNF-alpha inhibitors for ankylosing spondylitis Ankylosing spondylitis: an overview Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-alpha therapy and other novel approaches Golimumab in radiographic and nonradiographic axial spondyloarthritis: a review of clinical trials Economic Theory and Self-Reported Measures of Presenteeism in Musculoskeletal Disease Ageing, musculoskeletal health and work Routine Assessment of Patient Index Data 3 score (RAPID3) correlates well with Bath Ankylosing Spondylitis Disease Activity index (BASDAI) in the assessment of disease activity and monitoring progression of axial spondyloarthritis.Anti-TNF-alpha therapy in ankylosing spondylitis.Reducing work disability in Ankylosing Spondylitis: development of a work instability scale for AS Searching for potential biomarkers that can be used as biomarkers for diagnosing ankylosing spondylitis.Long-term outcome of patients with active ankylosing spondylitis with etanercept-sustained efficacy and safety after seven years.Work outcome in yet undiagnosed patients with non-radiographic axial spondyloarthritis and ankylosing spondylitis; results of a cross-sectional study among patients with chronic low back pain.Multicenter validation of the value of BASFI and BASDAI in Chinese ankylosing spondylitis and undifferentiated spondyloarthropathy patients.International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis New treatment options in ankylosing spondylitis: a role for anti-TNFalpha therapy.Treatment of ankylosing spondylitis with TNF blockers: a meta-analysis.Exploring the diversity of conceptualizations of work (dis)ability: a scoping review of published definitions.Staging of patients with ankylosing spondylitis: a preliminary proposal Recent progress in ankylosing spondylitis treatment.Novel approaches in the treatment of ankylosing spondylitis and other spondyloarthritides.Withdrawal from labour force due to work disability in patients with ankylosing spondylitis.Work status and productivity costs due to ankylosing spondylitis: comparison of three European countries.Employment perspectives of patients with ankylosing spondylitis.Quality of life and work in patients with rheumatoid arthritis and ankylosing spondylitis of working age Direct costs of ankylosing spondylitis and its determinants: an analysis among three European countries.Initiation of biological agents in patients with ankylosing spondylitis: results of a Delphi study by the ASAS Group.Is avoidant coping independent of disease status and stable over time in patients with ankylosing spondylitis?Maintenance of improvement in spinal mobility, physical function and quality of life in patients with ankylosing spondylitis after 5 years in a clinical trial of adalimumab Expanding the armamentarium for the spondyloarthropathies.Ankylosing spondylitis: recent breakthroughs in diagnosis and treatment Impact of Fatigue in Rheumatic Diseases in the Work Environment: A Qualitative Study Developments and current pharmacotherapeutic recommendations for ankylosing spondylitis.A review of work-participation, cost-of-illness and cost-effectiveness studies in ankylosing spondylitis.Patients with ankylosing spondylitis have increased sick leave--a registry-based case-control study over 7 yrs.Anti-TNF-alpha therapy with infliximab in spondyloarthritides.Variables related to work productivity loss in patients with ankylosing spondylitis.Health-related quality of life in patients with ankylosing spondylitis: a comprehensive review.Ankylosing spondylitis functional and activity indices in clinical practice.Golimumab for the treatment of axial spondyloarthritis.

P2860

Q24186462-250EBF4B-3F78-4C7C-9305-330DF92F856B Q24246757-9D37949D-492C-4542-901C-96C8F537CD38 Q24675044-5A89DE31-CD9F-4565-B187-3F30F5C3E0BE Q24806367-23D156E4-A3DC-464E-AD05-CD57058F5E86 Q26738520-B22B2E01-65A6-430B-9BC1-FAA17FC9BF4A Q26741224-21C6AF0F-FADF-4BCE-8B60-E8AFACCE3092 Q26776450-AF8CD1FA-DA0B-4967-8A3E-6425C0830E0D Q30871532-C53F158B-3DD4-44B9-9268-176CE0CBCF4D Q33204138-42DBD4FC-C1FF-4F46-928F-91EF251075EB Q33468708-1A99457E-5227-4FA4-8235-9C75E956DA73 Q33579369-C356D970-8A11-4923-9ED9-5721424D1327 Q33766318-6F61AF45-2D70-4829-8119-2872F26F7238 Q33808563-9338620A-D1B0-4AA0-8AE7-97A5BE793775 Q34511356-E1A29E3B-984A-4F92-9FF2-FE7523A272B2 Q34536278-D6DD428A-0D7A-4A95-BCB1-E4D63E6B1876 Q34560574-F8ECB9FA-C1DA-418D-904B-ADF964485E97 Q34728162-812BFF11-BA21-44EF-A046-A21276A890EF Q34864506-AA0020A4-159F-4035-91A9-30A64F60F54F Q34967499-677BEF19-1A27-40E6-BFEA-F4193CE6A7C8 Q35040745-F355F016-52CE-425F-B1AB-19C2CFA800B0 Q35164736-FB50F4BA-7F1D-4C47-94B2-AF8C5DAC40B8 Q35549928-78DBEE65-1383-41F2-BE1D-27B9714D4072 Q35551561-3B3C3B94-5A50-436E-A989-FD44102FBD33 Q35551784-916FAD86-7F1B-44C3-B826-4E55AC95F3A4 Q35552212-579BFB62-0440-455B-9130-D2457BA5626D Q35552992-F69C55D2-080B-40D4-8216-2C4A086CA694 Q35553066-3FE642F7-B9BC-4388-997A-1ED96F3F0B5A Q35553329-8472DD3F-47FC-4C2E-B3D5-E7544743468E Q35759171-5C1BF8AA-B2F4-4882-9105-DC30CE1E66E3 Q35823657-62AD7B14-E239-4344-ABC4-355FEE4C8371 Q36143588-A29C352A-D5CD-4B46-8C68-B85399AF6797 Q36323983-9C445E9A-AAE8-4875-9444-58C07F1205AA Q36458447-C8D4AAB3-F3C4-4817-A047-FB8BDECE998D Q36611047-0E47B1C2-A59A-40CF-BF08-B544DB5BDF03 Q37100632-A4B7A8C3-8E8D-4E95-931E-7513EF62D10C Q37729028-B91625A1-30C6-4F57-9AE5-B447F077339B Q38139808-F2CEC9CE-3E0F-4C62-A29B-36B1A00A688F Q38246381-D4F949AD-D685-48D1-83A1-70B0A25D8485 Q38289559-83339098-5724-4390-81BD-3A04C31545CE Q38622217-6EEDC024-5402-437A-A6DF-3C58BDD779AE

P2860

Employment, work disability, and work days lost in patients with ankylosing spondylitis: a cross sectional study of Dutch patients

http://www.wikidata.org/entity/Q35550292

description

2001 nî lūn-bûn

@nan

2001 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2001 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2001年の論文

@ja

2001年論文

@yue

2001年論文

@zh-hant

2001年論文

@zh-hk

2001年論文

@zh-mo

2001年論文

@zh-tw

2001年论文

@wuu

name

Employment, work disability, a ...... tional study of Dutch patients

@ast

Employment, work disability, a ...... tional study of Dutch patients

@en

type

label

Employment, work disability, a ...... tional study of Dutch patients

@ast

Employment, work disability, a ...... tional study of Dutch patients

@en

prefLabel

Employment, work disability, a ...... tional study of Dutch patients

@ast

Employment, work disability, a ...... tional study of Dutch patients

@en

P1433

Q35550292-DDB8E1AA-390F-4BB7-B63D-E126639C9885

P1476

Q35550292-5F248229-DF09-48EA-B095-0B1910B0725F

P2093

Q35550292-26A4D5AB-7080-44B1-A1F5-8ECBD880ADB3

Q35550292-2E6C0973-BB4B-4123-8843-DF50AA8BB624

Q35550292-52D2088E-A39C-4300-BAA1-3BCC51BCB88C

Q35550292-7DBF0BAF-D19B-45A0-BA1E-254A5B28DDFF

Q35550292-AC6604F9-AC5C-4F6B-817E-314D448942B4

Q35550292-AEB90129-6F0A-459F-85C9-7E8C02C8BBF5

P2860

Q35550292-06A87956-CC43-422E-BF89-62320679D88B

Q35550292-29A1AF11-2A09-412D-8E4B-9C00339FB369

Q35550292-36E1EB7A-112B-4279-A706-A91E33C54E59

Q35550292-3A6C5A26-2B9D-4664-952B-521A458DE70E

Q35550292-4A2D11BB-D926-410C-9368-AC4BA9885DAA

Q35550292-5228F875-DBFF-4CBA-938E-87C960DC965B

Q35550292-61C62E1D-575A-44EB-BB44-A4607FA1332B

Q35550292-6B460B75-34E3-4EAD-8693-0D49A890516A

Q35550292-6E0C736E-D583-4891-B7DC-398F0FE6DE2D

Q35550292-7C915A65-2F2D-4EC6-A188-94690DFF1B98

P304

Q35550292-91736070-03AC-4327-A184-01EB969DAA75

P31

Q35550292-83F57D59-53F1-4183-ADB2-FE5A3DB5EB15

P356

Q35550292-260CC522-1873-4504-8A6D-866083DBC4DD

P407

Q35550292-4D110268-D66E-4B3C-A825-A4636CABC184

P433

Q35550292-3750CCE6-B5DF-44F4-9255-1930CB0BB903

P478

Q35550292-F8E08A5F-9DF4-4587-9BD3-03F96CF530C0

P577

Q35550292-CD73F0D7-ADC8-401D-A153-158E609649C0

P5875

Q35550292-4DEF7B14-D06B-4DB0-ACB2-39FBAA1D49B0

P698

Q35550292-675B8F3A-C221-46D0-AB50-5240309B2CBE

P921

Q35550292-ACC66C0A-4F24-4364-B079-AA539EB97081

Q35550292-D4281BCE-563B-4328-836C-F138AF7AC2BC

P932

Q35550292-F0AFF091-BB95-4E26-BAC8-13970036ECFB

P356

P1433

Annals of the Rheumatic Diseases

P1476

Employment, work disability, a ...... tional study of Dutch patients

@en

P2093

Boonen A

http://www.w3.org/2001/XMLSchema#string

Chorus A

http://www.w3.org/2001/XMLSchema#string

Miedema H

http://www.w3.org/2001/XMLSchema#string

van der Heijde D

http://www.w3.org/2001/XMLSchema#string

van der Linden S

http://www.w3.org/2001/XMLSchema#string

van der Tempel H

http://www.w3.org/2001/XMLSchema#string

P2860

A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index

Employment in ankylosing spondylitis.

Work disability in early rheumatoid arthritis

A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index.

Labour force participation among patients with rheumatoid arthritis.

Social and economic impacts of four musculoskeletal conditions. A study using national community-based data.

The economic cost and social and psychological impact of musculoskeletal conditions. National Arthritis Data Work Groups.

Primary ankylosing spondylitis, psoriatic and enteropathic spondyloarthropathy: a controlled analysis.

The economic impact of the rheumatic diseases in the United States.

A review of 100 patients with ankylosing spondylitis with particular reference to socio-economic effects.

P304

353-358

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/ARD.60.4.353

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

60

http://www.w3.org/2001/XMLSchema#string

P577

2001-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

277384764

http://www.w3.org/2001/XMLSchema#string

P698

11247865

http://www.w3.org/2001/XMLSchema#string

P921

P932

1753602

http://www.w3.org/2001/XMLSchema#string